HRP20192248T1 - Anti-tim3 antibodies and methods of use - Google Patents

Anti-tim3 antibodies and methods of use Download PDF

Info

Publication number
HRP20192248T1
HRP20192248T1 HRP20192248TT HRP20192248T HRP20192248T1 HR P20192248 T1 HRP20192248 T1 HR P20192248T1 HR P20192248T T HRP20192248T T HR P20192248TT HR P20192248 T HRP20192248 T HR P20192248T HR P20192248 T1 HRP20192248 T1 HR P20192248T1
Authority
HR
Croatia
Prior art keywords
antibody
sequence
seq
immunoconjugate
antibody according
Prior art date
Application number
HRP20192248TT
Other languages
Croatian (hr)
Inventor
Valeria Lifke
Guy Georges
Victor LEVITSKY
Oliver Ploettner
Stefan Seeber
Barbara Weiser
Ildiko WUENSCHE
Adrian ZWICK
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15790559.7A external-priority patent/EP3215532B1/en
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20192248T1 publication Critical patent/HRP20192248T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Claims (13)

1. Izolirano protutijelo koje se veže na TIM3, naznačeno time, da protutijelo sadrži sljedeće: i) VH sekvencu identifikacijskog broja sekvence SEQ ID NO:83 te VL sekvencu identifikacijskog broja sekvence SEQ ID NO:84, ili ii) VH sekvencu identifikacijskog broja sekvence SEQ ID NO:85 i VL sekvencu identifikacijskog broja sekvence SEQ ID NO:86.1. An isolated antibody that binds to TIM3, characterized in that the antibody contains the following: i) VH sequence of sequence identification number SEQ ID NO:83 and VL sequence of sequence identification number SEQ ID NO:84, or ii) VH sequence of SEQ ID NO:85 and VL sequence of SEQ ID NO:86. 2. Protutijelo prema patentnom zahtjevu 1, naznačeno time, da protutijelo sadrži sljedeće: VH sekvencu identifikacijskog broja sekvence SEQ ID NO:83 i VL sekvencu identifikacijskog broja sekvence SEQ ID NO:84.2. The antibody according to claim 1, characterized in that the antibody contains the following: VH sequence of SEQ ID NO:83 and VL sequence of SEQ ID NO:84. 3. Protutijelo prema patentnom zahtjevu 1, naznačeno time, da protutijelo sadrži sljedeće: VH sekvencu identifikacijskog broja sekvence SEQ ID NO:85 i VL sekvencu identifikacijskog broja sekvence SEQ ID NO:86.3. The antibody according to claim 1, characterized in that the antibody contains the following: VH sequence of SEQ ID NO:85 and VL sequence of SEQ ID NO:86. 4. Protutijelo prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da je ono IgG1 protutijelo pune duljine.4. An antibody according to any one of the preceding claims, characterized in that it is a full-length IgG1 antibody. 5. Protutijelo prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da je ono IgGl protutijelo pune duljine s mutacijama L234A, L235A i P329G (numeriranje prema EU indeksu Kabat).5. An antibody according to any one of the preceding claims, characterized in that it is a full-length IgG1 antibody with mutations L234A, L235A and P329G (numbering according to the EU Kabat index). 6. Izolirana nukleinska kiselina, naznačena time, da ona kodira protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva.6. An isolated nucleic acid, characterized in that it encodes an antibody according to any one of the preceding claims. 7. Stanica domaćina, naznačena time, da ona sadrži nukleinsku kiselinu prema ostvarenju 6.7. The host cell, characterized in that it contains the nucleic acid according to embodiment 6. 8. Postupak proizvodnje protutijela, naznačen time, da obuhvaća kultiviranje stanice domaćina prema ostvarenju 7, na način da se stvara protutijelo.8. The method of antibody production, characterized in that it includes the cultivation of the host cell according to embodiment 7, in such a way as to create an antibody. 9. Postupak prema patentnom zahtjevu 8, naznačen time, da dodatno obuhvaća preuzimanje protutijela iz stanice domaćina.9. The method according to patent claim 8, characterized by the fact that it additionally comprises the uptake of antibodies from the host cell. 10. Imunokonjugat, naznačen time, da sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 5 i citotoksični agens.10. Immunoconjugate, characterized in that it contains an antibody according to any one of claims 1 to 5 and a cytotoxic agent. 11. Farmaceutska formulacija, naznačena time, da sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 5 ili imunokonjugat prema patentnom zahtjevu 10 i farmaceutski prihvatljiv nosač.11. Pharmaceutical formulation, characterized in that it contains an antibody according to any one of claims 1 to 5 or an immunoconjugate according to claim 10 and a pharmaceutically acceptable carrier. 12. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 5 ili imunokonjugat prema patentnom zahtjevu 10, naznačeni time, da se koriste kao lijek.12. The antibody according to any one of claims 1 to 5 or the immunoconjugate according to claim 10, characterized in that they are used as medicine. 13. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 5 ili imunokonjugat prema patentnom zahtjevu 10, naznačeni time, da su za uporabu u liječenju raka.13. The antibody according to any of claims 1 to 5 or the immunoconjugate according to claim 10, characterized in that they are for use in the treatment of cancer.
HRP20192248TT 2014-11-06 2019-12-13 Anti-tim3 antibodies and methods of use HRP20192248T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192175 2014-11-06
EP15790559.7A EP3215532B1 (en) 2014-11-06 2015-11-05 Anti-tim3 antibodies and methods of use
PCT/EP2015/075820 WO2016071448A1 (en) 2014-11-06 2015-11-05 Anti-tim3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
HRP20192248T1 true HRP20192248T1 (en) 2020-03-06

Family

ID=51868077

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192248TT HRP20192248T1 (en) 2014-11-06 2019-12-13 Anti-tim3 antibodies and methods of use

Country Status (2)

Country Link
AR (1) AR102495A1 (en)
HR (1) HRP20192248T1 (en)

Also Published As

Publication number Publication date
AR102495A1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
HRP20211594T1 (en) Anti-pd1 antibodies and methods of use
HRP20201031T1 (en) Anti-ctla-4 antibodies and methods of use thereof
HRP20201600T1 (en) Anti-pd-1 antibody and use thereof
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CO2018013500A2 (en) Anti-pd-l1 antibodies and uses thereof
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
HRP20231579T1 (en) Anti-ctla-4 antibodies and methods of use thereof
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
HRP20201505T1 (en) Broadly-neutralizing anti-hiv antibodies
HRP20210096T1 (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
HRP20200745T1 (en) Cd123 binding agents and uses thereof
RU2017119543A (en) ANTI-TIM3 ANTIBODIES AND WAYS OF THEIR APPLICATION
MX2020001198A (en) Binding agents binding to pd-l1 and cd137 and use thereof.
JP2018064580A5 (en)
FI3137504T3 (en) Antibody binding to fcrn for treating autoimmune diseases
HRP20231456T1 (en) Anti-c5 antibodies and methods of use
MY192392A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
MX2020002666A (en) Anti- folate receptor alpha antibody conjugates and their uses.
PE20181270A1 (en) ANTIBODY THAT NEUTRALIZES THE HUMAN SYNCITIAL RESPIRATORY VIRUS
HRP20220891T1 (en) Antibodies, uses&methods
MX2017014908A (en) Trispecific binding proteins and methods of use.
HRP20211794T1 (en) Human antibodies to pd-1
PE20191403A1 (en) ANTI-OX40 ANTIBODIES AND THEIR USES
IL258215B (en) Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE